Author:
Ricklin Daniel,Mastellos Dimitrios C.,Reis Edimara S.,Lambris John D.
Publisher
Springer Science and Business Media LLC
Reference245 articles.
1. Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nat. Biotechnol. 25, 1265–1275 (2007).
2. Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256–1264 (2007).
3. Center for Drug Evaluation and Research. Application number: 125166, approval letter. Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125166s0000_APPROV.pdf (2007).
4. Center for Drug Evaluation and Research. Application number: 125166s172, approval letter. Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/125166Orig1s172-2.pdf (2011).
5. Fakhouri, F. & Fremeaux-Bacchi, V. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next? Nat. Rev. Nephrol. 9, 495–496 (2013).
Cited by
309 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献